VICKIE DOSCHER: Open Payments
NPI 1932442522 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 34 payments from 15 companies in 2025. Trend: 2023 $225 · 2024 $588 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $236 |
| ABBVIE INC. | 9 | $197 |
| Novo Nordisk Inc | 1 | $119 |
| Madrigal Pharmaceuticals | 1 | $80 |
| Janssen Biotech, Inc. | 1 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Merck Sharp & Dohme LLC | 1 | $27 |
| Ardelyx, Inc. | 1 | $26 |
Products named: NUCALA, SKYRIZI, Wegovy, REZDIFFRA, TRELEGY ELLIPTA, TREMFYA, RINVOQ, DUPIXENT.
Industry payments across VA — which companies pay providers there.
